MedCity News
DECEMBER 29, 2024
Through collaboration between regulators and healthcare stakeholders, telehealth prescribing can continue to expand treatment access while maintaining proven safety standards. The post Navigating Virtual Prescribing Policy Changes in 2025 appeared first on MedCity News.
Pharmaceutical Technology
DECEMBER 29, 2024
Nelistotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.
MedCity News
DECEMBER 29, 2024
Remodel Health received $100 million in funding from Oak HC/FT and Hercules Capital. The post Remodel Health Secures Over $100M to Fuel Expansion in the ICHRA Market appeared first on MedCity News.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Cancer.
Advertiser: ZoomInfo
Savvy B2B marketers know that a great account-based marketing (ABM) strategy leads to higher ROI and sustainable growth. In this guide, we’ll cover: What makes for a successful ABM strategy? What are the key elements and capabilities of ABM that can make a real difference? How is AI changing workflows and driving functionality? This Martech Intelligence Report on Enterprise Account-Based Marketing examines the state of ABM in 2024 and what to consider when implementing ABM software.
MedCity News
DECEMBER 29, 2024
Dr. Eric Topol pointed out that while initial findings on generative AI in clinical settings are promising, they may not withstand the complexities of real-world clinical practice. The post Dr. Eric Topol: Generative AI Studies Boast Promising Results, But Real-World Challenges Remain appeared first on MedCity News.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).
MedCity News
DECEMBER 29, 2024
These valuable caregivers do not need false claims, empty promises, or even more technology to stay on top of. They need access to health education and literacy, healthy food, and seamless self-efficacy tools. The post Despite Our Efforts, The Sandwich Generation is Still Missing These Key Ingredients appeared first on MedCity News.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.
MedCity News
DECEMBER 29, 2024
In this episode, were joined by Kathryn Schubert, president and CEO of the Society for Womens Health Research. Schubert discusses the trends in womens health that defined 2024 and what we can expect in the coming year. The post MedCity FemFwd: What the Future Holds for Women’s Health in 2025 appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy.
Advertiser: ZoomInfo
Over the last two years, there’s been a 76 percent increase in AI adoption across sales organizations. The reason for its rise? AI increases teams’ productivity by predicting and automating actions that require manual effort. In other words, the research that takes reps hours, AI can do in seconds. For sales teams, AI opens up a world of new possibilities, including automating outreach, identifying best-fit buyers, and keeping CRMs flush with fresh data.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL).
Pharmaceutical Technology
DECEMBER 29, 2024
Nelistotug is under clinical development by GSK and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Cancer.
Pharmaceutical Technology
DECEMBER 29, 2024
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma.
Advertiser: ZoomInfo
Modern go-to-market teams know it takes more than one email to break through the noise. Multiple touchpoints means more ways to get your pitch right — and, potentially, more ways to be wrong. The good news? Once you know how to write compelling, one-off emails to entice prospective customers, you can easily do the same across a short sequence of emails.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy.
Pharmaceutical Technology
DECEMBER 29, 2024
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL).
Expert insights. Personalized for you.
87 
Let's personalize your content